Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BRENTUXIMAB VEDOTIN Cause Neuropathy peripheral? 695 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 695 reports of Neuropathy peripheral have been filed in association with BRENTUXIMAB VEDOTIN (ADCETRIS). This represents 7.2% of all adverse event reports for BRENTUXIMAB VEDOTIN.

695
Reports of Neuropathy peripheral with BRENTUXIMAB VEDOTIN
7.2%
of all BRENTUXIMAB VEDOTIN reports
82
Deaths
174
Hospitalizations

How Dangerous Is Neuropathy peripheral From BRENTUXIMAB VEDOTIN?

Of the 695 reports, 82 (11.8%) resulted in death, 174 (25.0%) required hospitalization, and 19 (2.7%) were considered life-threatening.

Is Neuropathy peripheral Listed in the Official Label?

Yes, Neuropathy peripheral is listed as a known adverse reaction in the official FDA drug label for BRENTUXIMAB VEDOTIN.

What Other Side Effects Does BRENTUXIMAB VEDOTIN Cause?

Off label use (1,370) Pyrexia (693) Febrile neutropenia (684) Death (602) Neutropenia (561) Hodgkin's disease (512) Nausea (392) Diarrhoea (385) Anaemia (374) Thrombocytopenia (358)

What Other Drugs Cause Neuropathy peripheral?

LENALIDOMIDE (10,215) BORTEZOMIB (4,067) OXALIPLATIN (3,662) DEXAMETHASONE (3,543) PACLITAXEL (3,508) LEVOFLOXACIN (2,619) CIPROFLOXACIN (2,607) FLUOROURACIL (2,605) CYCLOPHOSPHAMIDE (2,565) POMALIDOMIDE (2,382)

Which BRENTUXIMAB VEDOTIN Alternatives Have Lower Neuropathy peripheral Risk?

BRENTUXIMAB VEDOTIN vs BREO ELLIPTA BRENTUXIMAB VEDOTIN vs BREXANOLONE BRENTUXIMAB VEDOTIN vs BREXPIPRAZOLE BRENTUXIMAB VEDOTIN vs BREXUCABTAGENE AUTOLEUCEL BRENTUXIMAB VEDOTIN vs BRIGATINIB

Related Pages

BRENTUXIMAB VEDOTIN Full Profile All Neuropathy peripheral Reports All Drugs Causing Neuropathy peripheral BRENTUXIMAB VEDOTIN Demographics